bevacizumab + trastuzumab + cetuximab

This is a combination therapy consisting of three monoclonal antibodies—bevacizumab, trastuzumab, and cetuximab. Each targets a different pathway involved in cancer progression: - Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis (the formation of new blood vessels) essential for tumor growth. - Trastuzumab is a humanized monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2), inhibiting proliferation and survival of HER2-overexpressing cancer cells. - Cetuximab is a chimeric monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), preventing activation by endogenous ligands and inhibiting downstream signaling pathways involved in cell proliferation. This combination has been explored in clinical research settings for advanced cancers where multiple oncogenic pathways are implicated, but it does not have an established unique brand name or widespread regulatory approval as a fixed combination. Each component has individual approvals for specific indications such as metastatic colorectal cancer (bevacizumab, cetuximab), HER2-positive breast and gastric cancers (trastuzumab), and head & neck squamous cell carcinoma (cetuximab)[1][4][6].